Frontiers in Neuroscience, 16, 947563
doi: 10.1056/NEJMoa2511774
Many patients are on a combination of an SGLT2 inhibitor with a GLP-1 receptor agonist or tirzepatide (a dual agonist) and have incredible success without adverse reactions, but we are still figuring out the patient characteristics that would put them at higher risk of poor outcomes. Bagley is the senior editor of Endocrine News
Retatrutide targets three hormone receptors (GLP-1, GIP, and glucagon), while Ozempic targets one (GLP-1) and Mounjaro targets two (GLP-1 and GIP)
Donnelly, D
Because the causes of inflammation vary widely, GLP-1 and GLP-1/GIP medications meaningfully improve some inflammatory pathways (especially metabolically driven inflammation)but not all., This guide explains: How inflammation shows up in different organ systems Which inflammatory pathways semaglutide and tirzepatide actually improve Why they do not treat autoimmune disease, fibromyalgia, or chronic pain What early research suggestsand why we must be cautious What Is Inflammation